# Neumora Therapeutics, Inc.: financial statements, quarterly

NMRA · Nasdaq · CIK 1885522 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nmra.md) · [Financials](/companies/nmra/financials.md) · [Filings](/companies/nmra/filings.md) · [Insiders](/companies/nmra/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nmra/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [41.6](/filings/0000950170-24-125437.md) | [38.9 d](/filings/0000950170-25-030401.md) | [45.8](/filings/0000950170-25-069311.md) | [48.6](/filings/0000950170-25-104138.md) | [60.6](/filings/0001193125-25-269446.md) | [45.9 d](/filings/0001193125-26-130388.md) | [52.2](/filings/0001193125-26-211825.md) | [38.7](/filings/0001193125-26-350370.md) | [40.5](/filings/0001193125-25-269446.md) | [44.7 d](/filings/0001193125-26-130388.md) | [38.6](/filings/0001193125-26-211825.md) | [29.3](/filings/0001193125-26-350370.md) |
| Operating income | $m | [(56.9)](/filings/0000950170-24-125437.md) | [(114) d](/filings/0000950170-25-030401.md) | [(60.1)](/filings/0000950170-25-069311.md) | [(63.8)](/filings/0000950170-25-104138.md) | [(76.6)](/filings/0001193125-25-269446.md) | [(62.9) d](/filings/0001193125-26-130388.md) | [(70.9)](/filings/0001193125-26-211825.md) | [(54.0)](/filings/0001193125-26-350370.md) | [(57.7)](/filings/0001193125-25-269446.md) | [(58.5) d](/filings/0001193125-26-130388.md) | [(52.9)](/filings/0001193125-26-211825.md) | [(42.2)](/filings/0001193125-26-350370.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-25-269446.md) | [0.0 d](/filings/0001193125-26-130388.md) | [0.0](/filings/0001193125-26-211825.md) | [0.3](/filings/0001193125-26-350370.md) | [0.7](/filings/0001193125-25-269446.md) | [0.8 d](/filings/0001193125-26-130388.md) | [1.4](/filings/0001193125-26-211825.md) | [1.4](/filings/0001193125-26-350370.md) |
| Income tax | $m | not reported | not reported | not reported | [0.1](/filings/0000950170-25-104138.md) | [0.1](/filings/0001193125-25-269446.md) | [0.0 d](/filings/0001193125-26-130388.md) | [0.1](/filings/0001193125-26-211825.md) | [0.0](/filings/0001193125-26-350370.md) | [0.0](/filings/0001193125-25-269446.md) | [0.0 d](/filings/0001193125-26-130388.md) | [0.0](/filings/0001193125-26-211825.md) | [0.0](/filings/0001193125-26-350370.md) |
| Net income | $m | [(53.0)](/filings/0000950170-24-125437.md) | [(109) d](/filings/0000950170-25-030401.md) | [(53.7)](/filings/0001193125-25-269446.md) | [(58.7)](/filings/0001193125-25-269446.md) | [(72.5)](/filings/0001193125-25-269446.md) | [(58.8) d](/filings/0001193125-26-130388.md) | [(68.0)](/filings/0001193125-26-350370.md) | [(52.7)](/filings/0001193125-26-350370.md) | [(56.8)](/filings/0001193125-25-269446.md) | [(59.5) d](/filings/0001193125-26-130388.md) | [(53.5)](/filings/0001193125-26-350370.md) | [(43.1)](/filings/0001193125-26-350370.md) |
| Diluted EPS | $ per share | [(1.14)](/filings/0000950170-24-125437.md) | not reported | [(0.34)](/filings/0000950170-25-069311.md) | [(0.37)](/filings/0000950170-25-104138.md) | [(0.45)](/filings/0001193125-25-269446.md) | not reported | [(0.42)](/filings/0001193125-26-211825.md) | [(0.33)](/filings/0001193125-26-350370.md) | [(0.35)](/filings/0001193125-25-269446.md) | not reported | [(0.30)](/filings/0001193125-26-211825.md) | [(0.23)](/filings/0001193125-26-350370.md) |
| Basic EPS | $ per share | [(1.14)](/filings/0000950170-24-125437.md) | not reported | [(0.34)](/filings/0000950170-25-069311.md) | [(0.37)](/filings/0000950170-25-104138.md) | [(0.45)](/filings/0001193125-25-269446.md) | not reported | [(0.42)](/filings/0001193125-26-211825.md) | [(0.33)](/filings/0001193125-26-350370.md) | [(0.35)](/filings/0001193125-25-269446.md) | not reported | [(0.30)](/filings/0001193125-26-211825.md) | [(0.23)](/filings/0001193125-26-350370.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [412](/filings/0000950170-24-125437.md) | [374](/filings/0000950170-25-030401.md) | [183](/filings/0000950170-25-069311.md) | [151](/filings/0000950170-25-104138.md) | [276](/filings/0001193125-25-269446.md) | [142](/filings/0001193125-26-130388.md) | [127](/filings/0001193125-26-211825.md) | [125](/filings/0000950170-25-104138.md) | [129](/filings/0001193125-25-269446.md) | [183](/filings/0001193125-26-350370.md) | [147](/filings/0001193125-26-211825.md) | [117](/filings/0001193125-26-350370.md) |
| Current assets | $m | [526](/filings/0000950170-23-057424.md) | [478](/filings/0000950170-25-030401.md) | [443](/filings/0000950170-24-054448.md) | [398](/filings/0000950170-24-091737.md) | [349](/filings/0000950170-24-125437.md) | [314](/filings/0001193125-26-130388.md) | [255](/filings/0000950170-25-069311.md) | [223](/filings/0000950170-25-104138.md) | [177](/filings/0001193125-25-269446.md) | [191](/filings/0001193125-26-350370.md) | [153](/filings/0001193125-26-211825.md) | [125](/filings/0001193125-26-350370.md) |
| Total assets | $m | [545](/filings/0000950170-23-057424.md) | [496](/filings/0000950170-25-030401.md) | [450](/filings/0000950170-24-054448.md) | [404](/filings/0000950170-24-091737.md) | [353](/filings/0000950170-24-125437.md) | [317](/filings/0001193125-26-130388.md) | [257](/filings/0000950170-25-069311.md) | [224](/filings/0000950170-25-104138.md) | [178](/filings/0001193125-25-269446.md) | [191](/filings/0001193125-26-350370.md) | [154](/filings/0001193125-26-211825.md) | [125](/filings/0001193125-26-350370.md) |
| Current liabilities | $m | [29.1](/filings/0000950170-23-057424.md) | [25.1](/filings/0000950170-25-030401.md) | [24.6](/filings/0000950170-24-054448.md) | [23.1](/filings/0000950170-24-091737.md) | [31.7](/filings/0000950170-24-125437.md) | [29.9](/filings/0001193125-26-130388.md) | [28.4](/filings/0000950170-25-069311.md) | [21.2](/filings/0000950170-25-104138.md) | [25.8](/filings/0001193125-25-269446.md) | [32.5](/filings/0001193125-26-350370.md) | [30.1](/filings/0001193125-26-211825.md) | [27.8](/filings/0001193125-26-350370.md) |
| Total liabilities | $m | [32.1](/filings/0000950170-23-057424.md) | [27.1](/filings/0000950170-25-030401.md) | [25.7](/filings/0000950170-24-054448.md) | [23.2](/filings/0000950170-24-091737.md) | [31.8](/filings/0000950170-24-125437.md) | [29.9](/filings/0001193125-26-130388.md) | [28.4](/filings/0000950170-25-069311.md) | [40.9](/filings/0000950170-25-104138.md) | [45.7](/filings/0001193125-25-269446.md) | [87.2](/filings/0001193125-26-350370.md) | [83.2](/filings/0001193125-26-211825.md) | [80.7](/filings/0001193125-26-350370.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-25-269446.md) | not reported | [19.5](/filings/0000950170-25-104138.md) | [19.6](/filings/0001193125-25-269446.md) | [54.5](/filings/0001193125-26-350370.md) | [53.0](/filings/0001193125-26-211825.md) | [52.9](/filings/0001193125-26-350370.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [20.0](/filings/0000950170-25-104138.md) | [20.0](/filings/0001193125-25-269446.md) | [60.0](/filings/0001193125-26-130388.md) | [60.0](/filings/0001193125-26-211825.md) | [60.0](/filings/0001193125-26-350370.md) |
| Shareholders' equity | $m | [513](/filings/0000950170-24-125437.md) | [469](/filings/0001193125-26-130388.md) | [425](/filings/0001193125-25-269446.md) | [381](/filings/0001193125-25-269446.md) | [321](/filings/0001193125-25-269446.md) | [287](/filings/0001193125-26-350370.md) | [228](/filings/0001193125-26-350370.md) | [183](/filings/0001193125-26-350370.md) | [132](/filings/0001193125-25-269446.md) | [104](/filings/0001193125-26-350370.md) | [70.7](/filings/0001193125-26-350370.md) | [44.5](/filings/0001193125-26-350370.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(47.8) d](/filings/0000950170-24-125437.md) | [(51.4) d](/filings/0000950170-25-030401.md) | [(43.0)](/filings/0000950170-25-069311.md) | [(56.2) d](/filings/0000950170-25-104138.md) | [(33.5) d](/filings/0001193125-25-269446.md) | [(50.3) d](/filings/0001193125-26-130388.md) | [(59.4)](/filings/0001193125-26-211825.md) | [(52.4) d](/filings/0001193125-26-350370.md) | [(46.6) d](/filings/0001193125-25-269446.md) | [(48.0) d](/filings/0001193125-26-130388.md) | [(46.4)](/filings/0001193125-26-211825.md) | [(39.5) d](/filings/0001193125-26-350370.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-125437.md) | [0.0 d](/filings/0000950170-25-030401.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2022-09-30) | period not labelled (2023-03-31) | period not labelled (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [27.6](/filings/0000950170-23-057424.md) | [29.3](/filings/0000950170-24-054448.md) | [30.1](/filings/0000950170-24-091737.md) | [46.7](/filings/0000950170-24-125437.md) | [158](/filings/0000950170-25-069311.md) | [159](/filings/0000950170-25-104138.md) | [160](/filings/0001193125-25-269446.md) | [161](/filings/0001193125-26-211825.md) | [162](/filings/0001193125-26-350370.md) | [162](/filings/0001193125-25-269446.md) | [180](/filings/0001193125-26-211825.md) | [185](/filings/0001193125-26-350370.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 187,895,912 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001193125-26-350370.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.